FDA Considerations for Ketamine Tablet

Ketamine tablet exists in a legally complex but entirely lawful regulatory space. For a broader overview of what this means for patients, see our guide on compounded ketamine tablets. Understanding the FDA's current position on ketamine tablet — including why it is off-label, how compounding regulations apply, and what future approval pathways might look like — helps patients and prescribers navigate this landscape with confidence.

Current Regulatory Status

What Is Approved

The FDA has approved two ketamine-related products:

1. Ketalar (ketamine hydrochloride injection): Approved in 1970 as a general anesthetic for use in surgical and diagnostic procedures. The approval is for parenteral (injectable) administration only.
2. Spravato (esketamine nasal spray): Approved in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation or behavior. Esketamine is the S-enantiomer of ketamine.

No ketamine tablet formulation has received FDA approval for any indication — psychiatric, pain-related, or otherwise.

Off-Label Use: Legal but Unregulated

Off-label prescribing is the practice of using an FDA-approved drug for an indication, population, dose, or route of administration not specified in its approved labeling. Off-label prescribing is:

• Legal in the United States
• Common across medical specialties (an estimated 20 percent of all prescriptions are off-label)
• Based on prescriber judgment and available scientific evidence
• Not directly regulated by the FDA at the prescribing level

When a physician prescribes ketamine tablet for depression or chronic pain, they are engaging in legal off-label prescribing. The prescriber assumes responsibility for the decision based on their clinical assessment of risk-benefit for the individual patient.

The FDA and Off-Label Promotion

While off-label prescribing is legal, pharmaceutical manufacturers are prohibited from promoting their drugs for off-label uses. This restriction applies to Ketalar — the manufacturer cannot market injectable ketamine for oral psychiatric use. This prohibition is one reason the pharmaceutical industry has been relatively slow to develop FDA-approved oral formulations: the commercial incentive requires a formal approval pathway.

DEA Scheduling and Controlled Substance Requirements

Ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification reflects its recognized medical use and moderate abuse potential.

Key DEA requirements for ketamine prescribing include:

• Prescribers must hold a valid DEA registration to prescribe Schedule III substances
• Prescriptions may be written for up to a 90-day supply (state laws may be more restrictive)
• Refills are permitted for Schedule III substances (up to 5 refills within 6 months)
• Prescriptions may be transmitted electronically, by phone (for oral prescription), or in writing, depending on state law
• Emergency prescribing rules apply as with other Schedule III drugs

During the COVID-19 public health emergency, the DEA allowed telehealth prescribing of controlled substances without an initial in-person evaluation. These emergency flexibilities have been extended multiple times, with permanent rules still being finalized as of 2024.

Compounding Regulations: The 503A Framework

Because no FDA-approved ketamine tablet tablet exists, patients obtain ketamine tablet through compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

503A Requirements

503A compounding pharmacies must:

• Compound based on a valid prescription for an identified individual patient
• Use pharmaceutical-grade ingredients from registered API suppliers
• Comply with USP standards (USP 795 for non-sterile compounding)
• Be licensed by their state pharmacy board
• Not create commercial copies of FDA-approved products (the "essentially a copy" prohibition)

The "Essentially a Copy" Issue

A complication arose when the FDA took the position that compounding a drug that is essentially a copy of an FDA-approved product is impermissible under 503A. This created some uncertainty about compounding ketamine, since ketamine injection is FDA-approved.

However, the FDA's guidance and enforcement focus has primarily targeted sterile products like injectable drugs rather than oral formulations that are distinctly different in form and route. Compounded ketamine tablet tablets, troches, and capsules have continued to be available through compounding pharmacies, and this practice has not been subject to FDA enforcement action.

503B Outsourcing Facilities

503B facilities operate under stricter FDA oversight and can produce larger batches. Some 503B facilities have produced ketamine-containing products, and the regulatory landscape for 503B ketamine compounding has been actively debated.

FDA's Position on Ketamine Clinic Oversight

The FDA has expressed concern about the rapid expansion of ketamine clinics and at-home ketamine programs, particularly regarding:

• Patient selection and safety screening
• Adequacy of monitoring during and after treatment
• Risk of diversion of compounded ketamine
• Quality of compounded preparations used in these settings

The FDA and DEA have engaged in joint education and enforcement efforts aimed at ensuring ketamine prescribing occurs within appropriate medical frameworks.

Pathways to Future FDA Approval

Several pathways could lead to FDA-approved ketamine tablet formulations:

New Drug Application (NDA)

A pharmaceutical company would need to conduct FDA-required clinical trials demonstrating safety and efficacy of a specific oral formulation for a defined indication (e.g., maintenance of antidepressant response in TRD). This pathway requires substantial investment but would result in a fully approved, commercially marketable product.

Several companies were in various stages of ketamine tablet development as of 2024, including programs focused on extended-release formulations for depression maintenance.

Breakthrough Therapy Designation

The FDA grants Breakthrough Therapy designation to expedite development of drugs for serious conditions when preliminary evidence suggests substantial improvement over available therapies. Ketamine tablet for TRD could potentially qualify, given the unmet need and compelling existing evidence.

505(b)(2) Pathway

This pathway allows applicants to rely on existing published literature and the FDA's prior findings about approved drugs to support a new NDA. For ketamine tablet, a company might rely on the body of published pharmacokinetic and clinical data to reduce the de novo research burden.

What Patients Should Know

For patients currently using or considering ketamine tablet:

1. It is legal and commonly prescribed off-label — you are not in any legal gray area as a patient
2. The absence of FDA approval means your insurer may not cover it
3. Quality varies between compounding pharmacies; PCAB accreditation matters
4. As the regulatory landscape evolves, requirements and access may change
5. Future FDA approval of an oral formulation could expand insurance coverage significantly

The FDA's evolving approach to ketamine reflects the broader tension in American medicine between the pace of clinical innovation and the regulatory processes designed to ensure safety and efficacy.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• FDA: Approved Drug Products — U.S. Food and Drug Administration searchable database of approved drug products and therapeutic equivalents